Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a supplement duo quiet PCOS-Linked inflammation?

NCT ID NCT07821073

Disease control Sponsor: Khyber Medical University Peshawar Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 15, 2026 · Last updated Sep 16, 2026 · Updated 1 time

Summary

Researchers are testing whether a daily combination of myo-inositol and folic acid can lower two markers of inflammation, NLR and CRP, in overweight women aged 25 to 35 with polycystic ovarian syndrome. The trial compares this supplement pair with metformin plus folic acid over three months. Fifty participants will be randomly assigned to one of the two groups, take their treatment daily, and give blood samples at the start and end of the study to measure the markers.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
myo-inositol plus folic acid
What this could lead to
If it works, myo-inositol plus folic acid could offer a supplement-based option for easing the low-grade inflammation linked to PCOS.
What could go wrong
This is a small, short study of 50 women, so any difference in inflammation markers may be modest or fade with longer use. Supplements can also cause stomach upset or other side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

50 people

The number who actually took part.

Started

Oct 2025

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

25 to 35 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * PCOS diagnosed women 25-35years and overweight (BMI25 to 29.9 ). Exclusion Criteria: * Ongoing PCOS treatment, major comorbidities e.g. CVD, endocrine disorders, malignancies, pregnancy or diabetes.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Inflammation biomarkers are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

polycystic ovary syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Inflammation biomarkers PCOS (polycystic ovary syndrome) Poly cystic ovary syndrome

Contacts and locations

Locations

  • Peshawar Health Center

    Peshawar, Kpk, 25000, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.